These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Multiple sclerosis patients and immunomodulation therapies: the potential role of new MRI techniques to assess responders versus non-responders. Tedeschi G; Gallo A Neurol Sci; 2005 Dec; 26 Suppl 4():S209-12. PubMed ID: 16388360 [TBL] [Abstract][Full Text] [Related]
5. Overview of the management of relapsing-remitting multiple sclerosis and practical recommendations. Gallo P; Van Wijmeersch B; Eur J Neurol; 2015 Oct; 22 Suppl 2():14-21. PubMed ID: 26374509 [TBL] [Abstract][Full Text] [Related]
6. MRI as an outcome in multiple sclerosis clinical trials. Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945 [TBL] [Abstract][Full Text] [Related]
7. Randomized, open-label study to evaluate patient-reported outcomes with fingolimod after changing from prior disease-modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design. Cascione M; Wynn D; Barbato LM; Pestreich L; Schofield L; McCague K J Med Econ; 2013 Jul; 16(7):859-65. PubMed ID: 23647445 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. Rotstein DL; Healy BC; Malik MT; Chitnis T; Weiner HL JAMA Neurol; 2015 Feb; 72(2):152-8. PubMed ID: 25531931 [TBL] [Abstract][Full Text] [Related]
9. New treatments and treatment goals for patients with relapsing-remitting multiple sclerosis. Fox EJ; Rhoades RW Curr Opin Neurol; 2012 Feb; 25 Suppl():S11-9. PubMed ID: 22398660 [TBL] [Abstract][Full Text] [Related]
10. Impact of diagnosis and early treatment on the course of multiple sclerosis. Noyes K; Weinstock-Guttman B Am J Manag Care; 2013 Nov; 19(17 Suppl):s321-31. PubMed ID: 24494633 [TBL] [Abstract][Full Text] [Related]